Patents Issued in April 17, 2018
-
Patent number: 9943593Abstract: The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position (21), a leucine changed to alanine at position (111) and a methionine changed to an arginine at position (51). Another M protein mutant includes a glycine changed to a glutamic acid at position (22) and a methionine changed to an arginine at positions (48) and (51). These new rVSVs having the mutant M are significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31° C., and of poor replication or incapable of replication at about 37° C. or higher.Type: GrantFiled: June 26, 2014Date of Patent: April 17, 2018Inventors: Chil-Yong Kang, Gyoung Nyoun Kim
-
Patent number: 9943594Abstract: The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R).Type: GrantFiled: October 10, 2012Date of Patent: April 17, 2018Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.Inventors: Martine Jasson, Vanessa Marks, Xiaohong Huang, Allen Radin
-
Patent number: 9943595Abstract: The present invention provides, among other things, a method of intra-articular delivery of messenger RNA (mRNA), comprising administering into a joint of a subject in need of delivery a composition comprising an mRNA encoding a protein, such that the administering of the composition results in expression of the protein encoded by the mRNA in the joint.Type: GrantFiled: December 4, 2015Date of Patent: April 17, 2018Assignee: TRANSLATE BIO, INC.Inventors: Frank DeRosa, Michael Heartlein
-
Patent number: 9943596Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, ‘c-Met/EGFR dual inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor.Type: GrantFiled: November 23, 2015Date of Patent: April 17, 2018Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Jimin Lee, Bo Gyou Kim, Seungja Oh, Kyung Ah Kim, Powei Lin, Saet Byoul Lee
-
Patent number: 9943597Abstract: Methods and compositions for treating conditions including liver dysfunction, e.g., associated with fatty liver; glucose intolerance; and others, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations.Type: GrantFiled: August 17, 2011Date of Patent: April 17, 2018Assignee: Immuron LimitedInventors: Yaron Ilan, Gadi Lalazar, Tomer Adar, Meir Mizrahi, Ami Ben-Ya'acov
-
Patent number: 9943598Abstract: A radio- or chemo-sensitizing compound is described herein. The compound comprises a nanoparticle and attached to the nanoparticle; (i) a DNA repair inhibitor; and (ii) a nuclear localization signal element (NLS); each optionally attached via one or more linker moieties.Type: GrantFiled: May 28, 2013Date of Patent: April 17, 2018Assignee: THE UNIVERSITY OF BIRMINGHAM EDGBASTONInventor: Boris Kysela
-
Patent number: 9943599Abstract: The present inventors have shown that electroporation with calcium ions are efficient on cutaneous and subcutaneous nodules. In particular the present inventors here disclose that a solution comprising calcium ions (Ca2+) with a concentration of at least 0.1 M is extremely useful in a method of treating a neoplasm, such as cancer with means for causing transient permeabilization of the cell membranes of at least part of the neoplasm before, during and/or after administration of said solution, wherein said solution is administered with a ratio of 0.2 to 0.8 of the volume of said part of the neoplasm.Type: GrantFiled: December 21, 2012Date of Patent: April 17, 2018Assignee: HERLEV HOSPITALInventors: Karen Julie Gehl, Stine Krog Frandsen, Jens Ole Eriksen, Hanne Margrethe Gissel Hyldkrog, Pernille Højman Jensen
-
Patent number: 9943600Abstract: A method for stabilising a human blood protein or human blood plasma protein with a molecular weight of >10 KDa by adding melezitose to a solution comprising the human blood protein or human blood plasma protein with a molecular weight of >10 KDa.Type: GrantFiled: April 4, 2014Date of Patent: April 17, 2018Assignee: OCTAPHARMA AGInventors: Elsa Ivarsson, Josefin Knutsson, Brita Rippner, Ulrika Nilsson, Irene Agerkvist
-
Patent number: 9943601Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.Type: GrantFiled: March 23, 2016Date of Patent: April 17, 2018Assignee: Coherus Biosciences, Inc.Inventors: Mark Manning, Brian Murphy
-
Patent number: 9943602Abstract: The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.Type: GrantFiled: May 2, 2014Date of Patent: April 17, 2018Assignee: SDG, Inc.Inventors: W. Blair Geho, John R. Lau
-
Patent number: 9943603Abstract: The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes a diversity element which potentially binds to a target molecule with a dissociation constant of less than 300 ?M and a linker element connected to the diversity element. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to said diversity element, and is capable of forming a reversible covalent bond or non-covalent interaction with a binding partner of the linker element. The monomers can be covalently or non-covalently linked together to form a therapeutic multimer or a precursor thereof. Also disclosed is a method of screening for therapeutic multimer precursors which bind to a target molecule associated with a condition and a method of screening for linker elements capable of binding to one another.Type: GrantFiled: July 29, 2014Date of Patent: April 17, 2018Assignees: Cornell University, Purdue Research FoundationInventors: Francis Barany, Maneesh Pingle, Donald Bergstrom, Sarah Filippa Giardina
-
Patent number: 9943604Abstract: Provided herein are compounds comprising one or more therapeutic nucleosides and one or more targeting groups. In certain embodiments, the compounds further comprise one or more oligonucleotides. In certain embodiments, a targeting group comprises one or more N-Acetylgalactosamine.Type: GrantFiled: September 19, 2014Date of Patent: April 17, 2018Assignee: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Thazha P. Prakash
-
Patent number: 9943605Abstract: The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.Type: GrantFiled: December 23, 2011Date of Patent: April 17, 2018Assignee: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, Stephanie Allums-Donald, Sean M. Culbertson
-
Patent number: 9943606Abstract: Dendritic polypeptides useful for the delivery of therapeutic agents into cells are disclosed, together with their methods of preparation. These dendritic polypeptides serve as carriers of drugs, siRNA, aptamers and plasmid DNA in the treatment of various diseases, including cancer.Type: GrantFiled: January 12, 2015Date of Patent: April 17, 2018Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Ki-Bum Lee, Prasad Subramaniam, Dipti N. Barman
-
Patent number: 9943607Abstract: Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.Type: GrantFiled: May 9, 2012Date of Patent: April 17, 2018Assignee: Biothera, Inc.Inventors: Nandita Bose, Anissa S. H. Chan, Michael E. Danielson, Mary A. Antonysamy, John P. Vasilakos, Keith B. Gorden, Steven M. Leonardo, William J. Grossman
-
Patent number: 9943608Abstract: In some embodiments, the present disclosure pertains to compositions for nucleic acid delivery into cells. In some embodiments, the composition comprises: (1) a cationic polymer unit comprising a plurality of polymeric arms, where the plurality of polymeric arms comprise poly(aspartic acid) derivatives; and (2) a nucleic acid associated with the cationic polymer unit. In some embodiments, the cationic polymer unit comprises a linker covalently associated with the plurality of polymeric arms. In some embodiments, the cationic polymer unit has a dendritic shape. In some embodiments, the cationic polymer unit has a star-like shape. In some embodiments, the cationic polymer unit is biodegradable. Further embodiments of the present disclosure pertain to methods of delivering a nucleic acid into cells by introducing into the cells one or more of the compositions of the present disclosure.Type: GrantFiled: November 13, 2013Date of Patent: April 17, 2018Assignee: BAYLOR COLLEGE OF MEDICINEInventors: Jin Wang, Fude Feng
-
Patent number: 9943609Abstract: Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently an Auristatin compound. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.Type: GrantFiled: January 19, 2016Date of Patent: April 17, 2018Assignee: Mersana Therapeutics, Inc.Inventors: Aleksandr V. Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Charles E. Hammond, Cheri A. Stevenson, Natalya D. Bodyak, Patrick R. Conlon, Dimitry R. Gumerov
-
Patent number: 9943610Abstract: The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.Type: GrantFiled: December 20, 2013Date of Patent: April 17, 2018Assignees: BioAlliance C.V., AbGenomics International Inc.Inventors: Rong-Hwa Lin, Shih-Yao Lin, Yu-Chi Hsieh, Chiu-Chen Huang
-
Patent number: 9943611Abstract: According to some embodiments herein, expression systems and methods for reversible gene expression are provided. In some embodiments, adeno-associated viral vectors encoding a gene product of interest and comprising a plurality of recombinase target sites are provided. In some embodiments, a source of recombinase is provided. In some embodiments, the gene product of interest is expressed, and the recombinase then induces recombination events between the recombinase target sites, thus reducing or eliminating expression of the gene product of interest.Type: GrantFiled: October 30, 2013Date of Patent: April 17, 2018Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Alejandro Benjamin Balazs, David Baltimore
-
Patent number: 9943612Abstract: Disclosed herein are polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, methods of engineering the polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, and methods of enhancing transcription, translation, and increasing stability of a polynucleotide.Type: GrantFiled: October 8, 2015Date of Patent: April 17, 2018Assignee: Seattle Children's HospitalInventors: Andrew M. Scharenberg, Kyle Jacoby, Alexandra E. Grier
-
Patent number: 9943613Abstract: A method of imaging a joint of a subject comprises administering to the subject an amount of a salt of DAB-4 linked nitroxide citrate effective to enhance an MRI image of the joint and taking an MRI image of said joint.Type: GrantFiled: October 21, 2013Date of Patent: April 17, 2018Inventor: Gerald M. Rosen
-
Patent number: 9943614Abstract: The invention relates to diagnostic, detection, screening and imaging methods. In various embodiments, methods of diagnosis, detection, screening and imaging include administering a cationic steroid antimicrobial or CSA to a subject having or at risk of having an infection or a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in an amount effective to diagnose or detect the infection or the hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject. In a particular aspect, a detectable CSA, namely CSA-13 labeled with 99mTc is used to detect the presence of an infection.Type: GrantFiled: June 16, 2009Date of Patent: April 17, 2018Assignee: BRIGHAM YOUNG UNIVERSITYInventor: Paul B. Savage
-
Patent number: 9943615Abstract: Disclosed herein are nanoparticles and method for manufacturing the same. The nanoparticle is essentially composed of albumin and polyethylene glycol, wherein the albumin is covalently crosslinked with the polyethylene glycol.Type: GrantFiled: November 13, 2015Date of Patent: April 17, 2018Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN R.O.CInventors: Su-Jung Chen, Chang-An Chen, Chung-Yen Li, Chu-Nian Cheng, Ming-Syuan Lin, Shu-Pei Chiu, Chih-Hsien Chang
-
Patent number: 9943616Abstract: A method for removing microorganisms from liquid samples and a nanofiber containing liquid filtration medium that simultaneously exhibits high liquid permeability and high microorganism retention. Microorganisms such as bacteria, particularly B. Diminuta, are removed from a liquid by passing the liquid through a porous nanofiber containing filtration medium having a B. Diminuta LRV greater than about 9, and the nanofiber(s) has a diameter from about 10 nm to about 1,000 nm. Another method for removing microorganisms such as bacteria and Mycloplasma, includes passing the liquid through a porous nanofiber containing filtration medium having a microorganism LRV greater than about 8, and the nanofiber(s) has a diameter from about 10 nm to about 1,000 nm. The filtration medium can be in the form of a fibrous electro spun polymeric nanofiber liquid filtration medium mat.Type: GrantFiled: August 30, 2017Date of Patent: April 17, 2018Assignee: EMD Millipore CorporationInventors: Mikhail Kozlov, Wilson Moya, Gabriel Tkacik
-
Patent number: 9943617Abstract: An inline intravenous (IV) fluid sterilization system can be located within directly upstream of the patient's access point, downstream of any breach points, so as to ensure fluid sterility. The chamber space between the walls is accessed by a fluid inlet port and a fluid outlet port between which the fluid flows. The inlet port is connected to a conduit/tubing from the fluid source and the outlet port is interconnected with a conduit/tubing that is free of breach points and interconnects to the patient access point. The inner wall allows for transmission of UV light into the fluid space. The walls define a space therebetween that is relatively small radially, allowing for a sufficient flow rate, but providing a large surface area and small fluid depth for exposure to the UV light. The UV light is provided by an elongated lamp within a cavity of the inner wall.Type: GrantFiled: June 9, 2014Date of Patent: April 17, 2018Assignee: B.B.R. Medical Innovations, Inc.Inventors: Corey A. Burchman, Steven D. Reinitz, Kathryn E. Boucher Bi, Renee N. Cottle
-
Patent number: 9943618Abstract: A UV illumination method includes moving a UV peripheral separate from a smart device to location associated with a plurality of target surfaces, selecting a UV illumination application executing upon the smart device, selecting an icon from within the UV illumination application, sending via a wireless communication mechanism of the smart device to the UV peripheral, instructions to turn on a UV light disposed in the UV peripheral in response to the selection of the icon, receiving via a wireless communication mechanism disposed in the UV peripheral, the instructions to turn on the UV light, illuminating, with the UV light within the UV peripheral, sanitizing UV light to the plurality of target surfaces other than surfaces of the smart device in response to the instructions, and thereafter terminating illuminating, with the UV light within the UV peripheral, the sanitizing UV light from the plurality of target surfaces.Type: GrantFiled: June 6, 2017Date of Patent: April 17, 2018Assignee: RAYVIO CORPORATIONInventors: Yitao Liao, Robert Walker, Doug Collins, Sheung Li
-
Patent number: 9943619Abstract: A sanitizing machine comprising a supporting structure which includes two compartments or chambers (A, B), wherein, when the machine is in stand-by, a first compartment (A) is open and is able to house at least one container or object (V) to sanitize, while a second compartment (B) of the machine houses a sliding door (SP), which hermetically and automatically closes (D3) the first compartment (A) when the machine is on. The method thereof provides for at least one type of sanitizing cycle, such as a ozone cycle, a sanitizing liquid cycle and a combined cycle.Type: GrantFiled: June 25, 2013Date of Patent: April 17, 2018Inventor: Mauro Toso
-
Patent number: 9943620Abstract: A scalable, portable and modular chlorine dioxide fumigant decontamination system having an activating area and a neutralizing area which may be housed separately or as a single operationally connected unit, and which may be configured as a closed loop system connected to a decontamination chamber for decontamination of articles, or as an open loop system for decontamination of interiors and large confined spaces, and employing a specialized activating cup that is permeable to air yet substantially impermeable to water and chlorine dioxide reaction by-products such that directing air through the activation cup releases nearly pure chlorine dioxide fumigant. Methods and articles relating to the system are also described.Type: GrantFiled: August 27, 2015Date of Patent: April 17, 2018Assignee: Controlled Performance with Gases, LLCInventors: Lawrence F. Bender, James F. Knoer
-
Patent number: 9943621Abstract: A modular, integrated, combination air purification and aroma diffuser includes a UV and catalytic oxidation germicidal cell and multiple filtrations as pre-treatment of air diffusing essential oils or other liquids as ultra-fine droplets entrained in airflow into enclosed, habitable spaces. Liquid microbicide, insecticide, fumigant, or aroma therapy is kept cleaner by eradication of microbes. Comparatively larger droplets are separated out and recycled to the reservoir after initial atomization. An electrical module, between a purifier and filters upstream and a diffuser downstream, includes a pump, a fan, and a controller for both. Staged, double-eduction, triple-separation processes include a micro-cyclone for quiet, well diffused flow of ultra-fine droplets.Type: GrantFiled: October 19, 2016Date of Patent: April 17, 2018Inventor: Earl Vaughn Sevy
-
Patent number: 9943622Abstract: Method for minimizing the sorption of tear lipids on frequent replacement, or extended-wear, contact lenses, the method comprising (a) contacting the contact lens selected from the group consisting of senofilcon A, lotrafilcon A, lotrafilcon B, and comfilcon A B with a lens care solution for a period of at least three hours to minimize the accumulation of tear lipids on the contact lens. The lens care solution comprises 0.5 ppm to 10 ppm ?-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-?-tris(2-hydroxyethyl) ammonium chloride; citrate, citric acid or a mixture thereof; and 0.005 wt. % to 0.05 wt. % hyaluronic acid. The method also includes (b) inserting the soaked contact lens into one's eye, and (c) repeating steps (a) and (b).Type: GrantFiled: September 24, 2013Date of Patent: April 17, 2018Assignee: Bausch & Lomb IncorporatedInventors: X. Michael Liu, Joseph A. Chinn, George L. Grobe, III, E. Peter Maziarz
-
Patent number: 9943623Abstract: Disposable absorbent articles assembled from a collection of components using an adhesive comprising an amorphous polyolefin composition and a heterophase polyolefin composition comprising amorphous character and crystalline blocks.Type: GrantFiled: December 19, 2016Date of Patent: April 17, 2018Assignee: The Procter & Gamble CompanyInventors: William L. Bunnelle, Robert Haines Turner
-
Patent number: 9943624Abstract: The invention provides novel surface coatings having surface polymer brushes with zwitterionic and antibiotics-conjugated side chains and synergistic anti-fouling and bactericidal properties. The surface coatings may be prepared using highly efficient surface-initiated “living” polymerization. The design of the surface polymer brushes are highly modular, allowing independent tuning of the anti-fouling and bactericidal properties, e.g., by varying the chemical nature of the zwitterionic motif and the antibiotic agent, the chemistry through which the antibiotic agent is conjugated to the polymer side chains, the molecular weight of the polymer brushes (e.g., thickness of coating and density of respective functional motifs), and the spatial arrangement of the respective functional motifs (e.g., homopolymers, block copolymers, random copolymers) to achieve optimal and sustained anti-infection outcome for a given application.Type: GrantFiled: November 24, 2013Date of Patent: April 17, 2018Assignee: University of MassachusettsInventors: Jie Song, Pingsheng Liu, David C. Ayers
-
Patent number: 9943625Abstract: The present invention relates to a magnesium alloy having controlled corrosion resistance properties, which comprises magnesium (Mg) and an alloying element and includes a magnesium phase and a phase composed of magnesium and the alloying element, wherein the difference in electrical potential between the magnesium phase and the phase composed of magnesium and the alloying element is greater than 0 V but not greater than 0.2 V.Type: GrantFiled: December 9, 2016Date of Patent: April 17, 2018Assignee: U&I CorporationInventors: Ja-Kyo Koo, Hyun-Kwang Seok, Seok-Jo Yang, Yu-Chan Kim, Sung-Youn Cho, Jong-Tack Kim
-
Patent number: 9943626Abstract: A granule form e d from a tubular body having an outer surface and an inner surface separated by a matrix, and at least one core defining an opening extending through the tubular body. The outer surface of the matrix is adapted to permit fluid flow into and out of the matrix.Type: GrantFiled: March 28, 2016Date of Patent: April 17, 2018Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventor: Daniel S. Oh
-
Patent number: 9943627Abstract: A method for using 3D printing technology produces personalized biomimetic drug-eluting coronary stent and the product thereof. The process of manufacturing stent, based on coronary angiography imaging data, measures the diameter of diseased coronary and conducts 3D reconstruction. A personalized stent for each patient according to diameter, length, and morphological characteristics of target vessel that suited to the lesion is produced. The coronary stent is formed from biodegradable poly-L-lactic acid (PLLA) or other materials. The stent is modeled by 3D printing and then coated with polymers carrying antiproliferative drug to reduce restenosis (the polymers is a mixture of antiproliferative drug and PDLLA at a ratio of 1:1).Type: GrantFiled: June 18, 2015Date of Patent: April 17, 2018Inventors: Yujie Zhou, Wei Sun, Qian Ma, Lei Zhang
-
Patent number: 9943628Abstract: A stent that includes a stent body and one or more weld joints, wherein the weld joints include a radiopaque material, and a method of making a stent that includes using a radiopaque filler material in a welding process.Type: GrantFiled: July 30, 2014Date of Patent: April 17, 2018Assignee: Medtronic Vascular Inc.Inventor: Syamala Rani Pulugurtha
-
Patent number: 9943629Abstract: Described herein are alarm systems for suction devices for reduced pressure therapy. Alarms systems provide alerts to the patient and/or practitioner regarding the ability of the suction device to continue to provide negative pressure to a tissue region. Alarm systems comprise a sensor mechanism, which is capable of detecting the position of a slidable seal within the suction device, and generating an alert. Certain variations of alarms systems comprise magnetic field sensitive switches and/or electric switches. Other variations of alarm systems comprise rotary encoders to detect the motion and location of constant force springs, which signal the notification mechanism to issue alerts accordingly. Described herein are alarm devices configured to retain a suction device therein and to attach the suction device to a patient. The alarm devices disclosed herein detect the depleted state of the suction device and are capable of retaining the suction device in a plurality of orientations.Type: GrantFiled: August 4, 2014Date of Patent: April 17, 2018Assignee: KCI Licensing, Inc.Inventors: Dean Hu, Thomas Yorkey, Evan Anderson, Kenneth Wu
-
Patent number: 9943630Abstract: A rotor for an axial-flow blood pump has blades projecting outwardly from a hub and channels between the blades. The blades incorporate hydrodynamic bearing surfaces capable of suspending the rotor during operation. The rotor has a configuration which provides superior pumping action and reduced shear of blood passing through the pump. The forwardly facing pressure surfaces of the blades may include outflow corner surface at their downstream ends. The outflow corner surfaces desirably slope rearwardly and intersect the rearwardly-facing suction surfaces of the blades at outflow ends of the blades.Type: GrantFiled: December 28, 2016Date of Patent: April 17, 2018Assignee: HeartWare, Inc.Inventor: Mustafa Ertan Taskin
-
Patent number: 9943631Abstract: A system and method for determining a concentration of total chlorine in dialysis water are provided. The system comprises a main unit housing a KI/water sample chamber and a sodium sulfate chamber. A first electrode pair bridges the two chambers and generates tri-iodide proportional to the amount of total chlorine in the water sample. A second electrode pair in contact with fluid in the KI/water sample detects an amount of tri-iodide generated by the first electrode pair. The system is suitable for use in connection with, or for incorporation into, a water purification system for generating dialysis fluid, and may include a display that alerts the user to stop or prevent a hemodialysis treatment if the total chlorine level exceeds a predetermined level.Type: GrantFiled: August 5, 2015Date of Patent: April 17, 2018Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Jeff White, Ye Chen, Yuanpang Samuel Ding, Joel Titus, Justin Rohde, Shincy Maliekkal, Kevin Cooper
-
Patent number: 9943632Abstract: A system for performing a peritoneal dialysis therapy includes at least one dialysis fluid pump, and a control unit operable with the at least one dialysis fluid pump to perform a plurality of peritoneal dialysis cycles, the cycles including a fill phase, a dwell phase and a drain phase. The control unit configured to (i) store a previously entered continuous cycling peritoneal dialysis (“CCPD”) therapy having a total prescribed fresh dialysate fill volume delivered over n cycles, the cycles performed over a total therapy duration, and (ii) automatically convert the CCPD therapy into a tidal peritoneal dialysis therapy having n+1 cycles, less a number of cycles already completed during the CCPD therapy, using the total prescribed fresh dialysis fill volume, and maintaining the total therapy duration.Type: GrantFiled: September 15, 2015Date of Patent: April 17, 2018Assignees: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SAInventors: Robert W. Childers, Ying-Cheng Lo, Peter A. Hopping
-
Patent number: 9943633Abstract: A medical device system including a physiological sensor and ultrafiltration unit senses a physiological signal in a patient and computes a fluid status measurement of the patient using the physiological signal. Ultrafiltration therapy is delivered to the patient according to a therapy delivery control parameter established in response to the fluid status measurement.Type: GrantFiled: June 23, 2016Date of Patent: April 17, 2018Assignee: Medtronic Inc.Inventors: Daniel C. Sigg, Sarah Anne Audet, Tommy D. Bennett, Dwight H. Warkentin
-
Patent number: 9943634Abstract: The present invention relates to a device for connecting at least one external functional device to an arrangement, wherein the device includes at least one first contact portion and at least one second contact portion for receiving the external functional device between the first contact portion and the second contact portion, and at least the first contact portion or the second contact portion is movable. It further relates to a method for connecting at least one external functional device to an arrangement by using the device of the present invention, as well as an arrangement which includes at least one device of the present invention.Type: GrantFiled: March 9, 2010Date of Patent: April 17, 2018Assignee: Fresenius Medical Care Deutschland GmbHInventors: Juergen Haecker, Uwe Lapp, Udo Waeber
-
Patent number: 9943635Abstract: An extracorporeal circulation device having high safety without increases in the circuit scale and the power consumption includes a main control unit responsible for control of a motor drive circuit so as to yield a blood flow rate per unit time set by a user. The motor drive circuit applies a drive signal corresponding to the set blood flow rate to a motor. A sub-control unit configured by a field programmable gate array (FPGA) detects the drive signal applied to the motor and monitors whether or not the drive signal falls within an allowable range corresponding to the set blood flow rate. If the drive signal outside the allowable range is applied, the main control unit is deemed to be in an abnormal state and the main control unit is completely stopped. Then, the sub-control unit takes over the subsequent processing.Type: GrantFiled: September 5, 2012Date of Patent: April 17, 2018Assignee: Terumo Kabushiki KaishaInventor: Takeharu Iwata
-
Patent number: 9943636Abstract: An apparatus for extracorporeal treatment of blood (1) comprising a treatment unit, a blood withdrawal line, a blood return line, a preparation line and a spent dialysate line. A control unit (10) is configured to calculate values of a parameter relating to treatment effectiveness based on measures of the conductivity in the spent dialysate line. The value of the effectiveness parameter is calculated using one or more values representative of the conductivity in the spent dialysate line obtained relying on a mathematical model.Type: GrantFiled: October 28, 2013Date of Patent: April 17, 2018Assignee: GAMBRO LUNDIA ABInventors: Francesco Fontanazzi, Alessandro Surace, Francesco Rosati
-
Patent number: 9943637Abstract: The present invention relates to novel microporous zirconium silicate compositions having a desired particle size distribution and methods of making those compositions. These compositions have an ideal particle size distribution for use ex vivo, for example in a dialysis exchange cartridge, yet retain many of the desirable properties of prior improved absorbers including high cation exchange capacity. Further, the new zirconium silicate molecular sieve absorbers can be manufactured using a technique that achieves the desired particle size distribution while eliminating the screening step that was previously necessary.Type: GrantFiled: March 14, 2013Date of Patent: April 17, 2018Assignee: ZS PHARMA, INC.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Patent number: 9943638Abstract: Centrifugation systems and methods are provided for separating blood into its constituent parts. Inner and outer walls of a centrifuge each include a projection which extends toward the other wall. A separation chamber is received in the centrifuge between the walls, with the chamber including an inlet port for flowing blood into the chamber, a plasma outlet port for flowing plasma out of the chamber, and a red cell outlet port for flowing red blood cells out of the chamber. With the chamber received in the centrifuge between the walls, the first projection extends into the path of separated blood components flowing toward the plasma outlet port and prevents cellular blood components from flowing into the plasma outlet port. The second projection extends into the path of separated blood components flowing toward the red cell outlet port and prevents plasma from flowing into the red cell outlet port.Type: GrantFiled: October 28, 2016Date of Patent: April 17, 2018Assignee: Fenwal, Inc.Inventors: Kyungyoon Min, Richard I. Brown, John T. Foley, Brian C. Case
-
Patent number: 9943639Abstract: A hysteroscopic fluid management system includes a saline source with an electrolyte concentration, at least one pressure mechanism for circulating saline to and from a targeted site and through a filter having filter characteristics back to the source, and a controller. The controller provides a saline inflow in a first flow path to the site and a saline outflow in a second flow path from the site through the filter and back to the source at a controlled flow rate. A diagnostic or therapeutic procedure is performed at the site in the presence of the saline. The filter characteristics and the controlled flow rate are selected to (1) cause substantially no change in the electrolyte concentration in the saline, (2) to prevent hemolysis of greater than 5% of filtered red blood cells exposed to the saline, and/or (3) to minimize effect on prothrombin time of plasma exposed to the filter.Type: GrantFiled: January 30, 2014Date of Patent: April 17, 2018Assignee: BOSTON SCIENTIFIC SCIMED, INC.Inventors: Aaron Germain, Kyle Klein
-
Patent number: 9943640Abstract: A rectal drainage appliance is disclosed comprising a tubular element having an inflatable balloon at a distal end for anchoring the appliance in the rectum. The appliance includes one or more of: (i) first and second auxiliary lumens communicating with the inflatable balloon to provide independent inflation and pressure monitoring paths coupled to the balloon; (ii) a pressure state indicator defined by a mechanical element configured to flip between first and second states or shapes responsive to sensed pressure; and (iii) a collapsible auxiliary lumen larger than the inflation lumen, and configured to permit admission of irrigation fluid. The pressure state indicator may also be used in intestinal drains.Type: GrantFiled: May 1, 2009Date of Patent: April 17, 2018Assignee: Convatec Technologies, Inc.Inventor: Christopher Gregory
-
Patent number: 9943641Abstract: A package for a multi-component medical device is disclosed. The package includes a bottom portion with cavities providing individual access to different components of the medical device, thereby enabling a user to remove components from the package in any order without disturbing the remaining component or components. The package also includes a barrier affixed to the bottom portion for sealing the package.Type: GrantFiled: March 14, 2013Date of Patent: April 17, 2018Assignee: Becton, Dickinson and CompanyInventors: Matthew Morrison, Joshua David Horvath, James Sullivan, Stephen Lynn Richards, Victor Politis
-
Patent number: 9943642Abstract: A medical solution administration device includes a medical solution storage unit configured to store a medical solution; a channel part having a channel through which the medical solution is flowable from the medical solution storage unit to a living body; a piston; a cylinder part having an internal space; a driving unit configured to slide the piston between a press end position at which a front end of the piston is located at a first end of the internal space of the cylinder part and a pulled-back position at which the front end of the piston is located at a second end of the internal space of the cylinder part; and a seal located at an end of the cylinder part and positioned adjacent to the front end of the piston when the piston is in the pulled-back position, the seal being configured to circumferentially contact the piston.Type: GrantFiled: March 24, 2015Date of Patent: April 17, 2018Assignee: TERUMO KABUSHIKI KAISHAInventor: Akira Kondo